98%
921
2 minutes
20
The stable insertion of the retroviral genome into the host chromosomes requires the association between integration complexes and cellular chromatin via the interaction between retroviral integrase and the nucleosomal target DNA. This final association may involve the chromatin-binding properties of both the retroviral integrase and its cellular cofactor LEDGF/p75. To investigate this and better understand the LEDGF/p75-mediated chromatin tethering of HIV-1 integrase, we used a combination of biochemical and chromosome-binding assays. Our study revealed that retroviral integrase has an intrinsic ability to bind and recognize specific chromatin regions in metaphase even in the absence of its cofactor. Furthermore, this integrase chromatin-binding property was modulated by the interaction with its cofactor LEDGF/p75, which redirected the enzyme to alternative chromosome regions. We also better determined the chromatin features recognized by each partner alone or within the functional intasome, as well as the chronology of efficient LEDGF/p75-mediated targeting of HIV-1 integrase to chromatin. Our data support a new chromatin-binding function of integrase acting in concert with LEDGF/p75 for the optimal association with the nucleosomal substrate. This work also provides additional information about the behavior of retroviral integration complexes in metaphase chromatin and the mechanism of action of LEDGF/p75 in this specific context.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8565322 | PMC |
http://dx.doi.org/10.1093/nar/gkab886 | DOI Listing |
Viruses
August 2025
Andevir, University Bordeaux, CNRS, Microbiologie Fondamentale et Pathogénicité, UMR 5234, F-33000 Bordeaux, France.
Integrase is a key protein during HIV-1 replication as it catalyzes the integration of viral DNA into the host DNA. After several decades of research, highly potent and selective active site inhibitors have emerged. The new challenge is now to develop molecules with an original mode of action, targeting integrase out of its catalytic site.
View Article and Find Full Text PDFComput Biol Chem
December 2025
Amity Institute of Biotechnology, Amity University Maharashtra, Bhatan, Panvel, Navi Mumbai, Maharashtra 410206, India; Center for Drug Discovery and Development (CD3), Amity University Maharashtra, Bhatan, Panvel, Navi Mumbai, Maharashtra 410206, India. Electronic address:
HIV-1 drug resistance remains a major challenge in antiretroviral therapy, highlighting the need for new and more effective inhibitors. This study explores Zinc C293 as a potential dual inhibitor targeting two key HIV-1 enzymes: integrase (IN) and reverse transcriptase (RT). Initially identified through pharmacophore-based virtual screening, Zinc C293 was further analyzed using molecular docking and molecular dynamics (MD) simulations to understand its stability and interactions with IN.
View Article and Find Full Text PDFInt J Biol Macromol
July 2025
Biomedical Sciences and Molecular Biology, College of Medicine and Dentistry, James Cook University, Douglas, QLD 4811, Australia. Electronic address:
Human immunodeficiency virus (HIV) integrase is an important antiretroviral drug target. However, growing resistance towards integrase strand transfer inhibitors will need new drugs with distinct mechanisms of action. Highly efficient integrase activity assays are key tools for drug screening campaigns and the development of therapies addressing these resistance challenges.
View Article and Find Full Text PDFViruses
May 2025
Department of Genetics, Albert Einstein College of Medicine, Bronx, NY 10461, USA.
HIV-1 integrase (IN), an essential viral protein that catalyzes integration, also influences non-integration functions such as particle production and morphogenesis. The mechanism by which non-integration functions are mediated is not completely understood. Several factors influence these non-integration functions, including the ability of IN to bind to viral RNA.
View Article and Find Full Text PDFPharmaceuticals (Basel)
May 2025
Department of Health Informatics, College of Applied Medical Sciences, Qassim University, Buraydah 51452, Saudi Arabia.
This study aimed to develop a predictive model to classify and rank highly active compounds that inhibit HIV-1 integrase (IN). : A total of 2271 potential HIV-1 inhibitors were selected from the ChEMBL database. The most relevant molecular descriptors were identified using a hybrid GA-SVM-RFE approach.
View Article and Find Full Text PDF